[Fetal therapy of skeletal dysplasias]
1Department of Maternal and Fetal Medicine, Tohoku University Graduate School of Medicine, Miyagi Children's Hospital, Japan.
Insights
Fetal therapies for skeletal dysplasias, including enzyme, stem cell, and gene therapy, show promise. Early intervention may be crucial for severe cases, despite ongoing research and ethical considerations.
Area of Science:
- Regenerative Medicine
- Genetics
- Fetal Medicine
Context:
- Skeletal dysplasias present significant challenges due to abnormal development.
- Current treatments are often limited, especially for severe, congenital cases.
Purpose:
- To review current fetal therapy approaches for skeletal dysplasias.
- To assess the potential and limitations of enzyme replacement, stem cell transplantation, and gene therapy in utero.
Summary:
- Enzyme replacement therapy (ERT) for infantile hypophosphatasia is in clinical trials.
- Mesenchymal stem cell transplantation shows safety and efficacy in osteogenesis imperfecta cases.
- Gene therapy research, particularly in mouse models, demonstrates significant therapeutic potential.
Impact:
- Fetal therapies offer a potential paradigm shift for treating severe skeletal dysplasias.
- Further research is needed to address safety and ethical concerns for clinical application.
- Early fetal intervention could improve outcomes for conditions with severe developmental abnormalities at birth.
Abstract:
Three types of fetal therapy of skeletal dysplasias, as enzyme replacement, in utero stem cell transplantation, and gene therapy, are reviewed. Clinical trial of recombinant ALP for infantile hypophosphatasia has already started in Japan. In future, such enzyme replacement therapy is expected to be adapted to fetus. There are several reports of mesenchymal stem cell transplantation for osteogenesis imperfecta fetus. These case reports have showed that stem cell transplantation is safe and to some extent works in patients. No clinical trial for gene therapy has been reported. Recently, the study of gene therapy of using HPP fetal mouse showed an excellent therapeutic effect. Fetal therapy of skeletal dysplasias is still the stage of research because of the safety and the ethical issues. However, in order to treat severe cases of skeletal dysplasias which abnormal development has been already completed at birth, fetal therapy at an early stage would be demanded.
